Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.2900 (10.24%) ($8.2900 - $8.2900) on Fri. Aug. 12, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.22% (three month average) | RSI | 65 | Latest Price | $8.2900(10.24%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 5.6% a day on average for past five trading days. | Weekly Trend | TGTX advances 12.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) ACES(93%) QQQ(92%) XHB(83%) EWP(80%) ICLN(79%) | Factors Impacting TGTX price | TGTX will decline at least -3.61% in a week (0% probabilities). UUP(-49%) TBT(-49%) USO(-13%) XLE(-8%) XOP(-6%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.61% (StdDev 7.22%) | Hourly BBV | 1.3 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $7.74(7.11%) | 10 Day Moving Average | $6.92(19.8%) | 20 Day Moving Average | $6.65(24.66%) | To recent high | 0% | To recent low | 122% | Market Cap | $1.05b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |